Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: Relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment

Carlo Avolio, M. Filippi, C. Tortorella, M. A. Rocca, M. Ruggieri, F. Agosta, V. Tomassini, C. Pozzilli, S. Stecchi, P. Giaquinto, P. Livrea, M. Trojano

Research output: Contribution to journalArticle


Matrix metalloproteinase-9 (MMP-9) is involved in blood-brain barrier (BBB) disruption in active multiple sclerosis (MS), while MMP-2 seems to be associated with the chronic progressive phase of the disease. Recombinant interferon beta-1a (rIFNβ-1a) is effective in restoring the BBB. We studied the relationships between serum MMP-9, MMP-2, TIMX-1 and TIMP-2 and different magnetic resonance imaging (MRI) measures of disease activity in MS patients during treatment with rIFNβ-1a. Twenty-one relapsing-remitting (RR) MS patients underwent longitudinally simultaneous blood withdrawals and MRI (before and after standard dose (SD) and triple dose (TD) of gadolinium (Gd)) examinations before and during 48 weeks of rIFNβ-1a (Rebif® 22 mcg three times a week) treatment. Serum MMP-9, MMP-2, TIMP-1 and TIMP-2 were measured, MMP-9 to TIMP-1 and MMP-2 to TIMP-2 ratios were calculated and the numbers of Gd-SD, Gd-TD, new-Gd-SD, new-Gd-TD and new-T2 lesions counted. Serum MMP-9/TIMP-1 ratio (P

Original languageEnglish
Pages (from-to)441-446
Number of pages6
JournalMultiple Sclerosis Journal
Issue number4
Publication statusPublished - Aug 2005



  • Gadolinium triple dose
  • Interferon beta
  • MMP-2/TIMP-2
  • MMP-9/TIMP-1
  • MRI
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology

Cite this